Sushant Kumar Paikaray

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 5

Top Topics

Chronic Lymphocytic Leukemia

Diffuse Large B Cell Lymphoma

Top Venues

Indian journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Sushant Kumar Paikaray, Ajay Gogia, Lalit Kumar, Atul Sharma, Ahit Agni Biswas, Vishnubhatla Sreenivas, Soumya Mallick
A Phase III open-label randomized study to compare the efficacy of lenalidomide-rituximab with bendamustine-rituximab in treatment-naïve follicular lymphoma. Indian journal of cancer 60 (4) (2024)
Sushant Kumar Paikaray, Ajay Gogia, Lalit Kumar, Atul Sharma, Ahit Agni Biswas, Vishnubhatla Sreenivas, Soumya Mallick
A Phase III open-label randomized study to compare the efficacy of lenalidomide-rituximab with bendamustine-rituximab in treatment-naïve follicular lymphoma. Indian journal of cancer 60 (4) (2024)
Sushant Kumar Paikaray, Ajay Gogia, Lalit Kumar, Atul Sharma, Ahit Agni Biswas, Vishnubhatla Sreenivas, Soumya Mallick
A Phase III open-label randomized study to compare the efficacy of lenalidomide-rituximab with bendamustine-rituximab in treatment-naïve follicular lymphoma. Indian journal of cancer 60 (4) (2024)
Sushant Kumar Paikaray, Ajay Gogia, Lalit Kumar, Atul Sharma, Ahit Agni Biswas, Vishnubhatla Sreenivas, Soumya Mallick
A Phase III open-label randomized study to compare the efficacy of lenalidomide-rituximab with bendamustine- rituximab in treatment-naïve follicular lymphoma. Indian journal of cancer (2024)
Sushant Kumar Paikaray, Ajay Gogia, Lalit Kumar, Atul Sharma, Ahit Agni Biswas, Vishnubhatla Sreenivas, Soumya Mallick
A Phase III open-label randomized study to compare the efficacy of lenalidomide-rituximab with bendamustine- rituximab in treatment-naïve follicular lymphoma. Indian journal of cancer (2024)